Market Cap 394.78M
Revenue (ttm) 0.00
Net Income (ttm) -46.38M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,767,700
Avg Vol 1,265,372
Day's Range N/A - N/A
Shares Out 92.67M
Stochastic %K 2%
Beta 1.08
Analysts Sell
Price Target $22.00

Company Profile

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-c...

Industry: Biotechnology
Sector: Healthcare
Phone: 844 689 3939
Address:
630 5th Avenue, 20th Floor, New York, United States
GordonTheBest
GordonTheBest Mar. 21 at 10:09 PM
$AVXL any feedback on today’s ADPD presentation ?
0 · Reply
kitty7kitty
kitty7kitty Mar. 21 at 9:56 PM
$AVXL Just an observation- even though I have a lot of prior Fudsters blocked, the bad noise is much, much less this time around.
1 · Reply
ItsThrillhouse
ItsThrillhouse Mar. 21 at 8:25 PM
$AVXL Not for nothing, but there was no second article for Lecanemab that I can find during the period between its rejection and the reversed opinion. AE issued a disappoinment article immediately following rejection, but no further commentary until following the reversal, when it welcomed the mAb as an option. Ergo, this piece recommending precise and acceptable procedural elements for 2-73 is strong and active advocacy, and further convinces me they have had communication with SAG reviewers, whether in the context of CHMP meetings or externally. My spidey sense says they wanted to hear deeper insight before adopting a clear and inarguable stance. Now they are out on a limb with us. My WGT meter, against all odds, is rising.
1 · Reply
SpeedingTurtle
SpeedingTurtle Mar. 21 at 7:03 PM
$AVXL I am a firm believer that if you don't vote you cannot complain. So, If you message me or send me a comment I will send you the direct email to my CHMP contact and implore you to truly let your voice be heard not just on this board, but directly to the CHMP. Any third-party interventions are shared with the CHMP members and the applicant, so make sure your letters are proofread and of high quality. In your letter, you must state that you authorize your letter to be shared with the CHMP members and the applicant. My letter will be sent before midnight Sunday Pacific time as the Netherlands are 9 hours ahead of the West Coast. Part 2 Here is a snapshot of the email I sent yesterday to elicit the response from Dr. Lorenzo Guizzano.
2 · Reply
Georgejj
Georgejj Mar. 21 at 6:48 PM
$AVXL Anavex Life lead drug targets early Alzheimer's cause - new study highlights https://www.msn.com/en-us/health/other/anavex-life-lead-drug-targets-early-alzheimers-cause-new-study-highlights/ar-AA1Z3Inc Good luck and GOD bless,
0 · Reply
dtsguy13
dtsguy13 Mar. 21 at 5:42 PM
$AVXL I love this board with such knowledgeable members who explain all the scientific data well to people like me with no biological background. Here's to next week! OVER THE TOP
2 · Reply
jcolespartan
jcolespartan Mar. 21 at 5:42 PM
$AVXL If the EMA/CHMP decides to put the obligatory third trial “before” the conditional approval, does anyone know if that has happened to other EU drugs? If needed, how long would a third trial take? I am assuming another round of CHMP process approval would also be needed?
1 · Reply
RedShoulder_
RedShoulder_ Mar. 21 at 4:29 PM
$AVXL Alzheimer Europe position on EMA assessment of blarcamesine: The organisation would strongly support the granting of a conditional marketing authorisation with an obligation for the company to conduct an additional phase III clinical trial and to collect real world evidence from patients being treated in European countries. the medicine fulfils an unmet medical need the benefit-risk balance of the medicine is positive, the company can be required to provide comprehensive data post-authorisation and the benefit of the medicine's immediate availability to patients is greater than the risk inherent in the fact that additional data is still required. Alzheimer Europe therefore hopes that the re-examination will result in a decision that will allow people with early AD in Europe to access another treatment option. Thanks to Hosai on iHub for the link. (This support is very positive for the review). https://www.alzheimer-europe.org/policy/positions/alzheimer-europe-position-ema-assessment-blarcamesine
1 · Reply
Rudedog_1963
Rudedog_1963 Mar. 21 at 4:28 PM
0 · Reply
SpeedingTurtle
SpeedingTurtle Mar. 21 at 3:59 PM
1 · Reply
Latest News on AVXL
Anavex Life Sciences Corp. (AVXL) Q4 2025 Earnings Call Transcript

Nov 25, 2025, 11:53 AM EST - 4 months ago

Anavex Life Sciences Corp. (AVXL) Q4 2025 Earnings Call Transcript


Anavex Life Sciences Corp. (AVXL) Q3 2025 Earnings Call Transcript

Aug 12, 2025, 10:38 AM EDT - 7 months ago

Anavex Life Sciences Corp. (AVXL) Q3 2025 Earnings Call Transcript


Does Anavex's Alzheimer's Drug Actually Confer Benefit?

May 15, 2025, 8:49 PM EDT - 11 months ago

Does Anavex's Alzheimer's Drug Actually Confer Benefit?


Anavex Life Sciences Corp. (AVXL) Q2 2025 Earnings Call Transcript

May 13, 2025, 9:25 AM EDT - 11 months ago

Anavex Life Sciences Corp. (AVXL) Q2 2025 Earnings Call Transcript


GordonTheBest
GordonTheBest Mar. 21 at 10:09 PM
$AVXL any feedback on today’s ADPD presentation ?
0 · Reply
kitty7kitty
kitty7kitty Mar. 21 at 9:56 PM
$AVXL Just an observation- even though I have a lot of prior Fudsters blocked, the bad noise is much, much less this time around.
1 · Reply
ItsThrillhouse
ItsThrillhouse Mar. 21 at 8:25 PM
$AVXL Not for nothing, but there was no second article for Lecanemab that I can find during the period between its rejection and the reversed opinion. AE issued a disappoinment article immediately following rejection, but no further commentary until following the reversal, when it welcomed the mAb as an option. Ergo, this piece recommending precise and acceptable procedural elements for 2-73 is strong and active advocacy, and further convinces me they have had communication with SAG reviewers, whether in the context of CHMP meetings or externally. My spidey sense says they wanted to hear deeper insight before adopting a clear and inarguable stance. Now they are out on a limb with us. My WGT meter, against all odds, is rising.
1 · Reply
SpeedingTurtle
SpeedingTurtle Mar. 21 at 7:03 PM
$AVXL I am a firm believer that if you don't vote you cannot complain. So, If you message me or send me a comment I will send you the direct email to my CHMP contact and implore you to truly let your voice be heard not just on this board, but directly to the CHMP. Any third-party interventions are shared with the CHMP members and the applicant, so make sure your letters are proofread and of high quality. In your letter, you must state that you authorize your letter to be shared with the CHMP members and the applicant. My letter will be sent before midnight Sunday Pacific time as the Netherlands are 9 hours ahead of the West Coast. Part 2 Here is a snapshot of the email I sent yesterday to elicit the response from Dr. Lorenzo Guizzano.
2 · Reply
Georgejj
Georgejj Mar. 21 at 6:48 PM
$AVXL Anavex Life lead drug targets early Alzheimer's cause - new study highlights https://www.msn.com/en-us/health/other/anavex-life-lead-drug-targets-early-alzheimers-cause-new-study-highlights/ar-AA1Z3Inc Good luck and GOD bless,
0 · Reply
dtsguy13
dtsguy13 Mar. 21 at 5:42 PM
$AVXL I love this board with such knowledgeable members who explain all the scientific data well to people like me with no biological background. Here's to next week! OVER THE TOP
2 · Reply
jcolespartan
jcolespartan Mar. 21 at 5:42 PM
$AVXL If the EMA/CHMP decides to put the obligatory third trial “before” the conditional approval, does anyone know if that has happened to other EU drugs? If needed, how long would a third trial take? I am assuming another round of CHMP process approval would also be needed?
1 · Reply
RedShoulder_
RedShoulder_ Mar. 21 at 4:29 PM
$AVXL Alzheimer Europe position on EMA assessment of blarcamesine: The organisation would strongly support the granting of a conditional marketing authorisation with an obligation for the company to conduct an additional phase III clinical trial and to collect real world evidence from patients being treated in European countries. the medicine fulfils an unmet medical need the benefit-risk balance of the medicine is positive, the company can be required to provide comprehensive data post-authorisation and the benefit of the medicine's immediate availability to patients is greater than the risk inherent in the fact that additional data is still required. Alzheimer Europe therefore hopes that the re-examination will result in a decision that will allow people with early AD in Europe to access another treatment option. Thanks to Hosai on iHub for the link. (This support is very positive for the review). https://www.alzheimer-europe.org/policy/positions/alzheimer-europe-position-ema-assessment-blarcamesine
1 · Reply
Rudedog_1963
Rudedog_1963 Mar. 21 at 4:28 PM
0 · Reply
SpeedingTurtle
SpeedingTurtle Mar. 21 at 3:59 PM
1 · Reply
SpeedingTurtle
SpeedingTurtle Mar. 21 at 3:42 PM
$AVXL Part 1. In December last year, both Jesse, MayoMobile, and I sent in letters to the CHMP for the December meeting. As you recall, these letters were referred to as third-party interventions. I’ve had a strong suspicion, along with Termi0208 that next week will be our “For Opinion.” So, I sent an email to my CHMP contacts, yesterday about sending in another letter, third party intervention, in support of Anavex to see if I could gain any clues about the CHMP meeting next week and if Anavex was to be on the Agenda. I think it’s very clear from the language that Dr. Lorenzo Guizzaro uses that we are on the agenda next week; “Given the short timelines, I would ask you to send it as soon as possible on Monday…” See snapshot of the email below-
2 · Reply
Logic102
Logic102 Mar. 21 at 2:47 PM
$AVXL these logical points from Alzheimer's Europe are very important, appealing for a conditional approval: the medicine fulfils an unmet medical need the benefit-risk balance of the medicine is positive, the company can be required to provide comprehensive data post-authorisation and the benefit of the medicine's immediate availability to patients is greater than the risk inherent in the fact that additional data is still required. So sad that the US advocacy groups have given zero advocacy except for the Big Pharma failed drugs of course. Follow the money.
1 · Reply
Plexrec
Plexrec Mar. 21 at 2:22 PM
$AVXL Recent agenda ??? When is it expected ??? TIA
1 · Reply
ItsThrillhouse
ItsThrillhouse Mar. 21 at 2:07 PM
$AVXL Full support for conditional approval from the main European advocacy group. Unequivocally excellent news. By posting so late on the 16th, they may have already been in the room with SAG, etc, i.e. they were waiting on hearing formal assessments from neurological professionals. Thanks for spotting this, Alex.
2 · Reply
Hosai
Hosai Mar. 21 at 1:49 PM
$AVXL This seems like quite a big deal. Gives 'political cover' to CHMP to take more risk?
5 · Reply
Hosai
Hosai Mar. 21 at 1:39 PM
$AVXL I missed this before but looks like on the 16th March Alzheimers Europe did indeed put out a proper advocacy position document on behalf of Blarca (as they had also done for the MABS) - https://www.alzheimer-europe.org/policy/positions/alzheimer-europe-position-ema-assessment-blarcamesine
7 · Reply
papatrick
papatrick Mar. 21 at 12:53 PM
$AVXL Shorts this coming week:
0 · Reply
papatrick
papatrick Mar. 21 at 12:43 PM
$AVXL Benzinga is a Detroit-based financial media and data technology company that provides real-time news, actionable trading ideas, and market analysis for investors and traders. Known for its fast, actionable, and easy-to-consume news, Benzinga offers tools like Benzinga Pro and an API suite for brokerages and financial institutions.
0 · Reply
papatrick
papatrick Mar. 21 at 12:39 PM
$AVXL This MSN news... it is a huge mass media!!! The first time Anavex and Blarca appears in such media...and they did a scientific/facts/investment profile for the news!!! I think a huge amount of speculators will jump in with small amounts monday....followed by the whole world as soon as CHMP gives a positive signal!! How can they send a negative signal with peer reviewed papers signed by worlwide specialists....methodological issues were certainly corrected to meet their requirement and still gave p<0.05 for ADAS-COG...and OLE showed clearly disease modifying effect, ADL, brain scan...and post hoc ABCLEAR3 is 50% of ITT so it is easily proved that it's not a luck effect...with p values lower than 0.000001 kind of. Remains to scientifically define more clearly why Colagen gene is so important...but the MOA is already clearly demonstrated via ABCLEAR1 pre specified sub group with better results...Sigma 1 is the key...Col24A will be better explained with the Ph4 after CMA
0 · Reply
Georgejj
Georgejj Mar. 21 at 11:56 AM
$AVXL Anavex Life lead drug targets early Alzheimer's cause - new study highlights https://www.msn.com/en-us/health/other/anavex-life-lead-drug-targets-early-alzheimers-cause-new-study-highlights/ar-AA1Z3Inc Good luck and GOD bless,
0 · Reply
g0eCK
g0eCK Mar. 21 at 11:31 AM
$AVXL From what I remember, FDA and EMA assessments are timed by Anavex to be released very closely together?
3 · Reply
Termi0208
Termi0208 Mar. 21 at 10:07 AM
$AVXL Hetlioz and Blarca are similar cases: both were rejected in December and both received methodological criticisms. However Hetlioz is not appearing on Monday’s agenda because it was rejected this Monday via written procedure, meaning the case was already dead. It had concerns about the study design, the statistical analysis of the results, safety issues.. NO, you can’t assume that “if they rejected Hetlioz, Blarca is next.” In fact, it’s exactly the opposite. If Blarca were in the same situation and the methodological issues were truly insurmountable, it would also already have been rejected in writing and the case would be closed. Since that has not happened and considering that the SAG‑N has very likely already taken place, it’s clear that “they didn't close the door” on the case and it's still under real discussion. By the way, “methodological issues” have nothing to do with fraud; that’s complete BS and the undeniable fact is the existence of the SAG N.
4 · Reply